Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PL001 in Relapsed or Refractory B-cell Lymphoma
NCT05326243Phase 2Active, not recruiting
- Sponsor
- Pell Bio-Med Technology Co., Ltd.
- Start
- May 2022
- Primary completion
- Dec 2026
- Modality
- Autologous CAR-T
- Countries
- 1
01
Overview
A Phase 2 trial of PL001 in B cell lymphoma, sponsored by Pell Bio-Med Technology Co., Ltd.. Started May 2022; status: active, not recruiting.
02
Drugs
PL001
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT05326243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05326243.